Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYDW6J)

Drug Name
PGD2 Drug Info
Synonyms
Prostaglandin D2; prostaglandin D2; 11-Dehydroprostaglandin F2-alpha; 41598-07-6; BRN 2170623; UNII-RXY07S6CZ2; 11-Dehydroprostaglandin F2alpha; RXY07S6CZ2; CHEBI:15555; (5Z,13E,15S)-9alpha,15-Dihydroxy-11-oxoprosta-5,13-dienoate; (5Z,13E)-(15S)-9alpha,15-Dihydroxy-11-oxoprosta-5,13-dienoate; 9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoic acid; [3H]PGD2; (5E,13E)-9,15-DIHYDROXY-11-OXOPROSTA-5,13-DIEN-1-OIC ACID; Prosta-5,13-dien-1-oic acid, 9,15-dihydroxy-11-oxo-, (5Z,9-alpha,13E,15S)-; 11-dehydroprostaglandin F2-alpha
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
448457
ChEBI ID
CHEMBL1235252
CAS Number
CAS 41598-07-6
TTD Drug ID
DMYDW6J

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin E2 receptor EP1 (PTGER1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AS-013 DMD7XWS Thrombosis DB61-GB90 Phase 3 [14]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [6]
BUTAPROST DMVYNJZ Discovery agent N.A. Patented [15]
ZD6416 DM46JIR Pain MG30-MG3Z Discontinued in Phase 2 [16]
ONO-8130 DMBDCL4 Pollakiuria MF50.1 Terminated [17]
ONO-8711 DM2VRK7 Pain MG30-MG3Z Terminated [18]
U46619 DM13FX4 Discovery agent N.A. Investigative [6]
carbacyclin DMMBQYE Discovery agent N.A. Investigative [19]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [7]
cicaprost DM7ZJ4H Discovery agent N.A. Investigative [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP4 (PTGER4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [7]
RQ-00000007 (oral) DMMYTRU Pain MG30-MG3Z Phase 2 [20]
ONO-AE1-437 DMCUGI8 Asthma CA23 Phase 2 [21]
BGC-20-1531 DMS2MQ5 Migraine 8A80 Phase 2 [22]
IK-007 DMBLFPN Non-small-cell lung cancer 2C25 Phase 1/2 [23]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [24]
E7046 DMFVT43 Rectal adenocarcinoma 2B92 Phase 1 [25]
ONO-4232 DMO4SD2 Acute heart failure BD10-BD13 Phase 1 [26]
ONO-4578 DME63VK Solid tumour/cancer 2A00-2F9Z Phase 1 [25]
AN0025 DMGSYPY Aggressive cancer 2A00-2F9Z Phase 1 [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP2 (PTGER2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [15]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [28]
Alprostadil DMWH7NQ Aorta coarctation Approved [29]
Iloprost DMVPZBE Pulmonary arterial hypertension BB01.0 Approved [30]
Omidenepag isopropyl DMUX7Z8 Glaucoma/ocular hypertension 9C61 Approved [31]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [32]
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [7]
CP-533536 DMZEJLB Osteoporosis FB83.0 Phase 2 [33]
Taprenepag DM1TSHL Glaucoma/ocular hypertension 9C61 Phase 2 [34]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin D2 receptor 2 (PTGDR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [32]
Setipiprant DMZ61IA Asthma CA23 Phase 3 [35]
Fevipiprant DM4NX0C Asthma CA23 Phase 3 [36]
Ramatroban DMB8UQ3 Perennial allergic rhinitis CA08.03 Phase 2/3 [3]
AMG 853 DM973N4 Asthma CA23 Phase 2 [37]
ADC-3680 DM8GHIX Allergic rhinitis CA08.0 Phase 2 [38]
ARRY-502 DM17469 Allergic asthma CA23.0 Phase 2 [39]
QAV-680 DMIZYV1 Allergic rhinitis CA08.0 Phase 2 [40]
AP-761 DMISQOZ Asthma CA23 Phase 2 [41]
AZD1981 DMMCL9F Chronic obstructive pulmonary disease CA22 Phase 2 [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin D2 receptor (PTGDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [32]
Setipiprant DMZ61IA Asthma CA23 Phase 3 [43]
QAW-039 DMPCFXN Asthma CA23 Phase 3 [44]
AMG 853 DM973N4 Asthma CA23 Phase 2 [37]
ONO-4053 DMX4MVP Allergic rhinitis CA08.0 Phase 2 [45]
TS-022 DMMNXIW Atopic dermatitis EA80 Phase 2 [46]
S-555739 DMXDVNZ Allergy 4A80-4A85 Phase 2 [47]
MK-1029 DM8ZTW7 Asthma CA23 Phase 2 [38]
SAR-389644 DMA6O9R Allergic rhinitis CA08.0 Phase 1 [48]
192C86 DMQ8NTZ Thrombosis DB61-GB90 Phase 1 [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin F2-alpha receptor (PTGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [15]
Latanoprost DMI5OXG Ocular hypertension 9C61.01 Approved [50]
BOL-303259-X DM2EXC5 Open-angle glaucoma 9C61 Approved [51]
Tafluprost DMFC41K Glaucoma/ocular hypertension 9C61 Approved [52]
Carboprost Tromethamine DMS3508 Abortion JA00 Approved [53]
Travoprost DM20K91 Ocular hypertension 9C61.01 Approved [54]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [32]
PGF2ALPHA-IE DM5DAP3 Glaucoma/ocular hypertension 9C61 Phase 3 [55]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [56]
PDC-41 DM74YO8 Dysmenorrhea GA34.3 Phase 1 [57]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP3 (PTGER3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [7]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [56]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [7]
BUTAPROST DMVYNJZ Discovery agent N.A. Patented [15]
DG041 DMVO9WM Peripheral vascular disease BD4Z Discontinued in Phase 2 [58]
GR-63799X DM13GK8 Asthma CA23 Discontinued in Phase 1 [59]
U46619 DM13FX4 Discovery agent N.A. Investigative [19]
carbacyclin DMMBQYE Discovery agent N.A. Investigative [7]
butaprost (free acid form) DM5MZHP Discovery agent N.A. Investigative [19]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Poly polymerase 1 (PARP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [60]
Gefitinib DM15F0X Colon adenocarcinoma Approved [61]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [62]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [63]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [64]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [65]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [64]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [66]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [67]
Methotrexate DM2TEOL Anterior urethra cancer Approved [68]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Rho GDP-dissociation inhibitor 2 (ARHGDIB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [69]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [70]
Quercetin DM3NC4M Obesity 5B81 Approved [71]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [72]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [70]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [73]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [74]
Leflunomide DMR8ONJ Arthritis FA20 Approved [75]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [76]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [77]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Thyroglobulin (TG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [78]
Propylthiouracil DM6D7N8 Hyperthyroidism 5A02 Approved [79]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [80]
Testosterone DM7HUNW Hot flushes GA30 Approved [81]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [81]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [82]
Efavirenz DMC0GSJ Human immunodeficiency virus infection 1C62 Approved [80]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [76]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [83]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [84]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [71]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [85]
Fructose DM43AN2 Vomiting MD90 Approved [86]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [87]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [88]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [74]
Ketotifen DM74XKS Allergic conjunctivitis 9A60.02 Approved [89]
Riboflavin DM8YMWE Acne vulgaris ED80 Approved [11]
Leflunomide DMR8ONJ Arthritis FA20 Approved [75]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Acyl-protein thioesterase 2 (LYPLA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [90]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [91]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [92]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [84]
Arsenic DMTL2Y1 N. A. N. A. Approved [93]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [94]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [95]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [8]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Affected By Amyloid-beta precursor protein (APP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [96]
Selenium DM25CGV N. A. N. A. Approved [90]
Methotrexate DM2TEOL Anterior urethra cancer Approved [69]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [97]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [98]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [99]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [100]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [101]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [74]
Aluminium DM6ECN9 Hyperhidrosis EE00 Approved [102]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [94]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [103]
Diazepam DM08E9O Alcohol withdrawal Approved [104]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [105]
Desogestrel DM27U4Y Contraception QA21 Approved [105]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [103]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [103]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [106]
Quercetin DM3NC4M Obesity 5B81 Approved [107]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [78]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin D2 receptor (PTGDR) TTNVEIR PD2R_HUMAN Agonist [2]
Prostaglandin D2 receptor 2 (PTGDR2) TTQDMX5 PD2R2_HUMAN Agonist [3]
Prostaglandin E2 receptor EP1 (PTGER1) TTG1QMU PE2R1_HUMAN Agonist [4]
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Agonist [5]
Prostaglandin E2 receptor EP3 (PTGER3) TTPNGDE PE2R3_HUMAN Agonist [6]
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Agonist [6]
Prostaglandin F2-alpha receptor (PTGFR) TTT2ZAR PF2R_HUMAN Agonist [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acyl-protein thioesterase 2 (LYPLA2) OT03UIYC LYPA2_HUMAN Biotransformations [8]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Regulation of Drug Effects [9]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Regulation of Drug Effects [10]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A) OTHCDQ22 PRGC1_HUMAN Gene/Protein Processing [11]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Protein Interaction/Cellular Processes [12]
Rho GDP-dissociation inhibitor 2 (ARHGDIB) OT9PD6CS GDIR2_HUMAN Protein Interaction/Cellular Processes [12]
Thyroglobulin (TG) OT3ELHIJ THYG_HUMAN Gene/Protein Processing [13]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1891).
2 A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. Eur J Pharmacol. 1999 Jul 14;377(1):101-15.
3 CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
4 Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
5 Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51.
6 Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
7 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
8 Identification of the major prostaglandin glycerol ester hydrolase in human cancer cells. J Biol Chem. 2014 Dec 5;289(49):33741-53. doi: 10.1074/jbc.M114.582353. Epub 2014 Oct 9.
9 Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):177-87. doi: 10.1016/j.jsbmb.2009.12.009. Epub 2009 Dec 28.
10 Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. NPJ Aging Mech Dis. 2016 Jun 23;2:16012. doi: 10.1038/npjamd.2016.12. eCollection 2016.
11 A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1 expression and mitochondrial biogenesis. PLoS One. 2012;7(10):e46753. doi: 10.1371/journal.pone.0046753. Epub 2012 Oct 3.
12 Prostaglandin D(2) and J(2) induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochim Biophys Acta. 2005 Apr 15;1743(3):291-304.
13 15-Deoxy-Delta(12,14)-prostaglandin J(2) facilitates thyroglobulin production by cultured human thyrocytes. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1859-69. doi: 10.1152/ajpcell.2000.279.6.C1859.
14 Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
15 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
16 The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003 Jan;124(1):18-25.
17 ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain. 2011 Jun;152(6):1373-81.
18 Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.
19 The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
20 Clinical pipeline report, company report or official report of Avarx.
21 An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
22 BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
23 Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
24 Clinical pipeline report, company report or official report of Tempest Therapeutics.
25 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
26 ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
27 AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.
28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
29 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
30 Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
31 Clinical pipeline report, company report or official report of Santen Pharmaceutical.
32 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
33 Pfizer. Product Development Pipeline. March 31 2009.
34 A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
35 Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52.
36 Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207.
37 Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
38 Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
39 Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502).
40 Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91.
41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464)
42 Clinical pipeline report, company report or official report of AstraZeneca (2009).
43 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
44 Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015.
45 Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219.
46 Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14.
47 Clinical pipeline report, company report or official report of Shionogi (2011).
48 US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders.
49 Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145.
50 PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
51 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
52 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
53 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
54 Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
55 Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
56 IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
57 THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.
58 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
59 Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
60 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
61 Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
62 Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
63 Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
64 The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
65 Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
66 Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
67 Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
68 Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
69 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
70 Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
71 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
72 Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
73 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
74 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
75 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
76 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
77 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
78 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
79 Thyroid organotypic rat and human cultures used to investigate drug effects on thyroid function, hormone synthesis and release pathways. Toxicol Appl Pharmacol. 2012 Apr 1;260(1):81-8. doi: 10.1016/j.taap.2012.01.029. Epub 2012 Feb 8.
80 Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab. 2005 Oct;90(10):5663-71. doi: 10.1210/jc.2005-0367. Epub 2005 Jul 19.
81 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
82 Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab. 2003 Jul;88(7):3021-6. doi: 10.1210/jc.2002-021834.
83 Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles. Thyroid. 2007 Dec;17(12):1189-200. doi: 10.1089/thy.2007.0215.
84 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
85 Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
86 Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
87 Glucosamine-induced endoplasmic reticulum stress affects GLUT4 expression via activating transcription factor 6 in rat and human skeletal muscle cells. Diabetologia. 2010 May;53(5):955-65. doi: 10.1007/s00125-010-1676-1. Epub 2010 Feb 18.
88 AMPK activator acadesine fails to alleviate isoniazid-caused mitochondrial instability in HepG2 cells. J Appl Toxicol. 2017 Oct;37(10):1219-1224. doi: 10.1002/jat.3483. Epub 2017 May 29.
89 Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9. doi: 10.1016/j.taap.2016.04.007. Epub 2016 Apr 16.
90 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
91 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
92 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
93 Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
94 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
95 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
96 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
97 Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
98 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
99 Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 2000 Jun;130(2-3):209-16. doi: 10.1006/jsbi.2000.4285.
100 Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. J Neurochem. 2005 Nov;95(4):1059-68. doi: 10.1111/j.1471-4159.2005.03440.x. Epub 2005 Sep 7.
101 Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
102 Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis. 2005 Nov;8(2):117-27; discussion 209-15. doi: 10.3233/jad-2005-8204.
103 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
104 Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
105 Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
106 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
107 AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.